Unicycive Therapeutics’ (UNCY) Buy Rating Reaffirmed at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $4.00 target price on the stock.

Separately, Benchmark restated a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $5.50.

Unicycive Therapeutics Price Performance

Shares of NASDAQ:UNCY opened at $0.54 on Wednesday. The business’s 50-day moving average is $0.69 and its 200-day moving average is $0.51. Unicycive Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.82. The company has a market capitalization of $55.95 million, a price-to-earnings ratio of -0.56 and a beta of 2.30.

Institutional Trading of Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in Unicycive Therapeutics in the third quarter valued at approximately $29,000. Virtu Financial LLC lifted its holdings in shares of Unicycive Therapeutics by 566.8% in the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after purchasing an additional 62,881 shares in the last quarter. Bleakley Financial Group LLC acquired a new stake in Unicycive Therapeutics in the 3rd quarter valued at $33,000. Acuta Capital Partners LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter valued at $807,000. Finally, Walleye Capital LLC acquired a new position in Unicycive Therapeutics during the third quarter worth $2,040,000. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.